This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Eutilex Co., Ltd.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Hyuntae Son: Innovator in CAR-T Cell Therapy
Introduction
Hyuntae Son is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of immunotherapy, particularly in the development of CAR-T cell therapies. His innovative work has the potential to transform cancer treatment and improve patient outcomes.
Latest Patents
Hyuntae Son holds a patent for "GPC3 CAR-T Cell Compositions and Methods of Making and Using the Same." This patent represents a crucial advancement in the application of CAR-T cell technology, targeting GPC3, a protein associated with certain types of cancer.
Career Highlights
Hyuntae Son is currently employed at Eutilex Co., Ltd., a company dedicated to developing cutting-edge immunotherapeutic solutions. His work at Eutilex has positioned him as a key player in the field of cancer research and treatment.
Collaborations
He has collaborated with notable colleagues, including Byoung S Kwon and Kwanghee Kim, to further advance the research and application of CAR-T cell therapies. Their combined expertise enhances the potential for innovative breakthroughs in cancer treatment.
Conclusion
Hyuntae Son's contributions to CAR-T cell therapy exemplify the impact of innovative thinking in the medical field. His work continues to inspire advancements in cancer treatment and offers hope for patients worldwide.